U.S. Markets closed

Acorda Therapeutics, Inc. (ACOR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
0.6113-0.0159 (-2.54%)
At close: 04:00PM EST
0.5910 -0.02 (-3.32%)
After hours: 07:36PM EST

Acorda Therapeutics, Inc.

420 Saw Mill River Road
Ardsley, NY 10502
United States
914 347 4300

IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees118

Key Executives

NameTitlePayExercisedYear Born
Dr. Ron Cohen M.D.Founder, CEO, Pres & Director1.21MN/A1956
Dr. Burkhard Blank M.D.Interim Head of Drug Safety1.36MN/A1955
Mr. Michael A. Gesser M.B.A.Chief Financial OfficerN/AN/A1963
Mr. Robert MoralesInterim Principal Accounting Officer, Principal Financial Officer, VP of Fin. & ControllerN/AN/A1968
Ms. Felicia VonellaVP of Investor RelationsN/AN/AN/A
Mr. Neil S. Belloff Esq.Gen. Counsel & Corp. Sec.N/AN/A1960
Ms. Tierney SaccavinoExec. VP of Corp. CommunicationsN/AN/AN/A
Ms. Denise J. DucaExec. VP of HRN/AN/AN/A
Mr. Andrew Mayer J.D.Sr. VPN/AN/AN/A
Mr. Kerry M. ClemChief Commercial OfficerN/AN/A1970
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.

Corporate Governance

Acorda Therapeutics, Inc.’s ISS Governance QualityScore as of October 1, 2022 is 6. The pillar scores are Audit: 7; Board: 5; Shareholder Rights: 7; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.